



www.isctr.org

Translational Pathway for Medical Devices - Online Course -

**36 Multidisciplinary Lectures presented by Innovators,
Industry, Regulatory (FDA & EU), Reimbursement,
Practice Guideline, and Patients**

Target Audience:

**Inventors, Clinical and Basic Scientists, Interventional Cardiologists, Medical
Students, Engineers, Industry, Regulators, Payers, and Investors**

Introduction *(Total 2 hrs)*

- 1) **Welcome from the Course Directors (View for free online)**
 - Nabil Dib, MD, ISCTR *(42 mins 42 secs)*
 - Spencer King, MD, Emory University *(5 mins 50 secs)*
 - Anthony DeMaria, MD, University of California San Diego *(5 mins)*

 - 2) **Course Description (4 mins 45 secs)**

 - 3) **The Translational Pathway to Expedite Scientific Discovery to Patients**
 - Robert Califf, MD, FDA **(View for free online)** *(23 mins 45 secs)*

 - 4) **Meet the Legends of Innovation Panel Discussion (View for free online) (39 mins)**
 - John Simpson, MD, Avinger
 - Alain Cribier, MD, University of Rouen
 - Gary Roubin, MD, Brookwood Baptist Health
 - Richard Schatz, MD, Scripps Clinic
 - Julio Palmaz, MD, San Francisco
 - David Reuter, MD, PhD, Seattle Children's
 - Gregg Sutton, Surmodics, Inc.
 - Bram Zuckerman, MD, FDA
 - Gregg Stone, MD, Mt. Sinai
 - Spencer King, MD, Emory University
 - Magdi Yacoub, MD, Imperial College
 - James Muller, MD, InfraRedx
 - Charles Simonton, MD, Abbott Vascular
 - Neal Farnot, PhD, Cook Group
 - Stan Rowe, NXT Biomedical
-

Topics in Medical Device Development *(Total = 12 hrs)*

Topic 1: Concept/Innovation *(Total = 7 mins)*

- 1) **Choosing an Innovative Concept**
 - Todd Brinton, MD, Edwards Lifesciences *(7 mins 10 secs)*
-

Topic 2: Intellectual Property (Total = 5 mins)

2) **Intellectual Property**

- James Inskeep, Inskeep Intellectual Property Group (4 mins 45 secs)
-

Topic 3: Business Plan, Product Development, and Fundraising (Total = 6 mins)

3) **Business Plan, Product Development, and Fundraising**

- Stan Rowe, NXT Biomedical (6 mins)
-

Topic 4: Product Manufacturing (Total = 24 mins)

4) **Requirements for Medical Device Manufacturing & Iteration - FDA Point of View**

- Brad Quinn, FDA (9 mins 35 secs)

5) **Requirements for Medical Device Manufacturing & Iteration - Industry Point of View**

- Richard Rapoza, PhD, Abbott Vascular (14 mins 35 secs)
-

Topic 5: Preclinical Evaluation/Animal Model (Total = 1 hr)

6) **Advanced Cardiac Anatomy – Application in Translational Research Tailored to Current and Future Technology**

- Renu Virmani, MD, CV Path Institute (14 mins 10 secs)

7) **Large Animal Model for Heart Failure, Valvular Disease, Coronary Artery Disease, and Device Testing**

- Daniel Burkhoff, MD, Columbia University (15 mins 50 secs)

8) **Pre-Clinical Study Design & Endpoints for Device Evaluation – FDA Point of View**

- Judith Davis, DVM, MS, FDA (16 mins)

9) **Pre-Clinical Study Design & Endpoints for Device Evaluation – Investigator Point of View**

- Renu Virmani, MD, CV Path Institute (12 mins 40 secs)
-

Topic 6: Early Feasibility (Total = 31 mins)

10) **Early Feasibility Studies for Device Evaluation**

- Andrew Farb, MD, FDA (14 mins 50 secs)

11) **Current Challenges & Future Direction for Human Early Feasibility Study for Device Evaluation – Industry Point of View**

- David Reuter, MD, Seattle Children's Hospital (15 mins 35 secs)
-

Topic 7: Biostatistics (Total = 2 hrs 22 mins)

12) **Basic in Statistics – Clinical Study Design for Translational Research**

- Chris Mullin, PhD, NAMSA (16 mins)

13) **Basic Statistical Concepts**

- Chris Mullin, PhD, NAMSA (22 mins 25 secs)

14) **Sample Size and Power**

- Chris Mullin, PhD, NAMSA (22 mins 30 secs)

15) **Sensitivity and Specificity**

- Chris Mullin, PhD, NAMSA (9 mins 15 secs)

16) **Common Study Design**

- Chris Mullin, PhD, NAMSA (22 mins 50 secs)

17) **Phases of Translational Research**

- Chris Mullin, PhD, NAMSA (4 mins 15 secs)

18) **Statistics for Evaluation of Cardiovascular Diagnostic Devices**

- Chris Mullin, PhD, NAMSA (12 mins 40 secs)

19) **Pre-Clinical & Clinical Trial Design & Endpoints of Fast Track to Device Approval**

- Roseann White, PhD, Duke Research Institute (14 mins 45 secs)

20) **Advanced Statistical Methods for Translational Research**

- Chris Mullin, PhD, NAMSA (13 mins 45 secs)

21) **Clinical Endpoints/Surrogate Endpoints**

- Roseann White, PhD, Duke Research Institute (6 mins 15 secs)

Topic 8: Regulatory Approval (Total = 48 mins)

22) **Regulatory Requirement for Marketing Approval**

- Bram Zuckerman, MD, FDA ([View for free online](#)) (15 mins 20 secs)

23) **FDA Perspective on Transformative Regulatory Pathways & Device Innovation**

- Bram Zuckerman, MD, FDA (9 mins 10 secs)

24) **Regulatory Review of Cardiovascular Diagnostic Devices – FDA Perspective**

- Marco Cannella, PhD, FDA (9 mins 45 secs)

25) **Regulatory Review of Cardiovascular Devices – European Regulatory Perspective**

- Robert Byrne, MD, Heart Center, Germany ([View for free online](#)) (14 mins 10 secs)

Topic 9: Reimbursement (Total = 24 mins)

26) **CMS Criteria for Reimbursement for Cardiovascular Innovation**

- Joseph Chin, MD, Centers for Medicare and Medicaid Services (CMS) (13 mins 25 secs)

27) **Reimbursement for Diagnostic Devices**

- Lori Ashby, Centers for Medicare and Medicaid Services (CMS) (10 mins 35 secs)

Topic 10: Practice Guideline (Total = 32 mins)

28) **Practice Guideline Requirement for New Technology**

- Alice Jacobs, MD, Boston University (16 mins 20 secs)

29) **Guideline Requirements for Diagnostic Devices**

- Roxana Mehran, MD, Icahn School of Medicine, Mount Sinai (16 mins)

Topic 11: Technology Adoption (Total = 37 mins)

30) **Adoption of Technology**

- Ian Meredith, MD, Boston Scientific (7 mins 10 secs)

31) **Global Heart Health, Implications for Translational Research**

- Salim Yusuf, MD, World Federation of Cardiology (29 mins 25 secs)

Topic 12: Conflict of Interest (Total = 8 mins)

32) **Conflict of Interest and Product Development**

- Anthony DeMaria, MD, University of California San Diego (7 mins 45 secs)

Topic 13: Patients *(Total = 8 mins)*

33) The Patients Voice

- Mark Mercola, PhD, Stanford Cardiovascular Institute *(7 mins 35 secs)*
-

Panel Discussions *(Total = 2 hrs 3 mins)*

- Diagnostic Devices Development *(32 mins)*
- Device Development: Essential Concepts *(21 mins)*
- Requirements for CV Devices Approval *(36 mins 25 secs)*
- Clinical Endpoints & Biostatistics *(19 mins 30 secs)*
- Preclinical, Early Feasibility, and Safety Study for Device Development *(14 mins 20 secs)*

Total Course Hours = Approx. 12 hours